Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
TEL AVIV, Israel, Feb. 08, 2017 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat CNS and cognitive disorders, today announced that it will report its financial results for the year ended December 31, 2016 on Wednesday, February 15, at 8:30 am Eastern Time. The company also announced a corporate presentation at the BIO CEO & Investor Conference, being held on February 13-14, 2017 at the Waldorf Astoria in New York City.
| FY2016 Financial Results Conference Call & Webcast | |
| Wednesday, February 15th @ 8:30am Eastern Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Conference ID: | 63950344 |
| Webcast: | http://edge.media-server.com/m/p/662vg37q |
| Replays available through March 2, 2017 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 63950344 |
| BIO CEO & Investor Conference | |
| Tuesday, February 14th at 8:30am Eastern Time | |
| Location: | Waldorf Astoria, New York |
| Webcast: | http://www.veracast.com/webcasts/bio/ceoinvestor2017/54203411117.cfm |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of medications to treat CNS and cognitive disorders. For more information, please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-390-8964, Intl: +972-3-7299871 [email protected]
